Results 181 to 190 of about 120,862 (212)
Some of the next articles are maybe not open access.
Pathology of triple negative breast cancer
Seminars in Cancer Biology, 2021Triple negative breast cancer (TNBC) is a subtype of breast tumor lacking hormone receptors expression and HER2 gene amplification and represents 24 % of newly diagnosed breast neoplasms. In this review, pathological aspects of triple-negative breast cancer are illustrated, with particular attention to the seminal studies that defined this subtype of ...
Filippo, Borri, Annarita, Granaglia
openaire +2 more sources
Epidemiology of triple negative breast cancers [PDF]
Breast Disease, 2011 Triple negative (TN) breast cancers fail to express the three most common breast cancer receptors; i.e., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). Accumulating data demonstrate that epidemiological risk factor profiles also vary between TN (ER-PR-HER2-) and other breast cancers, especially ...
Gretchen L, Gierach +2 more
openaire +2 more sources
Local Treatment of Triple-Negative Breast Cancer
The Cancer Journal, 2021Abstract Triple-negative breast cancer, compared with other molecular subtypes, poses particular challenges for optimizing the timing and the extent of locoregional treatments. In the past, the combination of increased rates of both locoregional and distant recurrences led to a preference of radical surgery and extensive radiation therapy ...
Machiels, Melanie +3 more
openaire +3 more sources
Pharmacotherapy of triple-negative breast cancer
Expert Opinion on Pharmacotherapy, 2009The term 'triple-negative breast cancer' defines tumors that do not express estrogen receptors, progesterone receptors or Her2 on immunohistochemical analysis. This subgroup accounts for 15% of all types of breast cancer. Histologically, triple-negative breast cancers are poorly differentiated and are characterized by an aggressive clinical history.
Cagatay, Arslan +2 more
openaire +2 more sources
Immunotherapy in triple-negative breast cancer
Medical Oncology, 2017Breast cancer can be classified based on the expression or lack of expression of protein receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (Her2). The basal molecular subtype is mostly made up of breast cancers that do not express ER/PR or Her2, triple-negative breast cancers (TNBC) (Bertucci ...
Heather Katz, Mohamed Alsharedi
openaire +2 more sources
Triple-negative breast cancers
Expert Review of Anticancer Therapy, 2023Steven A, Narod, Rebecca, Dent
openaire +2 more sources
Immunohistochemistry for Triple-Negative Breast Cancer
2016Triple-negative breast cancers are a heterogeneous group of tumors that are, as yet, not entirely understood. Although triple-negative carcinomas are strictly defined as invasive carcinomas lacking expression of estrogen receptor, progesterone receptor, and HER2, some use the terms triple-negative and basal-like cancer synonymously.
Naidoo, Kalnisha, Pinder, Sarah E
openaire +3 more sources
Advanced Triple-Negative Breast Cancer
Seminars in Oncology NursingOur focus within this review is to summarize key advances and new therapeutic approaches within advanced triple-negative breast cancer. In addition, we highlight the importance of multidisciplinary management, discussing key issues for patients and importance of the supportive role that specialist nurses provide.Peer-reviewed literature, clinical ...
Grisma, Patel +2 more
openaire +2 more sources
Pembrolizumab in Triple-Negative Breast Cancer
New England Journal of Medicine, 2022Ryan, Sun, Lee-Jen, Wei
openaire +3 more sources